<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00632905</url>
  </required_header>
  <id_info>
    <org_study_id>AZ-CMX-03</org_study_id>
    <nct_id>NCT00632905</nct_id>
  </id_info>
  <brief_title>Bone Health Observational Study</brief_title>
  <acronym>BHOS</acronym>
  <official_title>A Prospective Study to Evaluate the Incidence of Skeletal Related Events In Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (ADT).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CMX Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CMX Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate Cancer patients treated with LHRH agonists (e.g., goserelin) lose Bone Mineral
      Density (BMD). Using a prospective, observational study design, we propose that monitoring
      how physicians manage Cancer Treatment Induced Bone Loss(CTIBL) in their patients. The gold
      standard for evaluating BMD is dual energy x-ray absorptiometry (DEXA). The proposed study
      will provide some of the first prospective data on the rates of Skeletal Related Events
      (SREs) in prostate cancer patients undergoing ADT and help develop official guidelines on the
      use of DEXA screening for prostate cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A consequence of ADT is the gradual bone loss, so-called cancer treatment induced bone loss
      (CTIBL). The current standard of care is the addition of Vitamin D and Calcium upon the
      initiation of ADT. Moreover, bisphosphonates are now being considered to treat and prevent
      CTIBL. However, bisphosphonates are costly, thus there is a desire to identify or target a
      specific subset of patients who would most benefit from the treatment.

      By obtaining baseline BMD and monitoring for Skeletal Related Events (SREs), we hope to
      identify that specific sub-set of patients who would most benefit from the treatment. Using a
      prospective, observational study design, we propose monitoring how physicians manage CTIBL in
      their patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density of the lumbar spine</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Safety</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">599</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Normal - BMD with T-score at or above -1.0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Osteopenic - BMD with T-score between -1.1 and -2.4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Osteoporotic - BMD with T-score at or below -2.5</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing to provide written Informed Consent.

          -  Patients for whom Androgen Deprivation Therapy (ADT) with Zoladex® is indicated for at
             least 1 year.

          -  Patients started on Zoladex® within the last 4 months.

        Exclusion Criteria:

          -  Patient had surgery or significant traumatic injury occurring within 1 month prior to
             consent.

          -  Known hypersensitivity to Goserelin Acetate or any of the components found in
             Zoladex®.

          -  Any concurrent condition that would make it undesirable, in the physician's opinion,
             for the subject to participate in the study or would jeopardize compliance with the
             protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard W Casey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CMX Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. John A. Warner</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V5G 1T4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Interior Medical Research Corporation</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 2H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanaimo Urology Associates</name>
      <address>
        <city>Nanaimo</city>
        <state>British Columbia</state>
        <zip>V9S 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Island Research Centre</name>
      <address>
        <city>Port Alberni</city>
        <state>British Columbia</state>
        <zip>V9Y 8C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Andreou Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruce W. Palmer Urology Inc.</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scotia</state>
        <zip>B4N 4K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jonathan L. Giddens</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6V 1B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brantford Urology Research Medical Arts Bldg.</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3R 4N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G. Kenneth Jansz Medicine Professional Corporation</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Richard Sowery</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7T 3K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guelph Urology Associates</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Alvaro Morales</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GU Trials Markham</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L6B 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mor Urology Inc</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3X 1W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Dental Bldg</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanley Flax Medicine Professional Corporation</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3B 3S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York-Finch Med Centre</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3N 2V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fe/Male Health Centres</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orillia Urology Associates</name>
      <address>
        <city>Orillia</city>
        <state>Ontario</state>
        <zip>L3V 7V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urotec</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahoney Medicine Professional Corporation</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2150935 Ontario Inc</name>
      <address>
        <city>Owen Sound</city>
        <state>Ontario</state>
        <zip>N4K 2J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawartha Urology Associates</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9H 1T6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Centre</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 2X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Allan Abramovitch</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1S 4V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Peter Roney</name>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <zip>K7A 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Urology Centre</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 4T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Arthur Place</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7E 6E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Edward Woods</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1P 2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Male Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Roger Buckley</name>
      <address>
        <city>Willowdale</city>
        <state>Ontario</state>
        <zip>M2K 2W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ABHM Associates</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8Y 4X9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Louis-Rene Barrette</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 6B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Recherches Cliniques Theradev</name>
      <address>
        <city>Granby</city>
        <state>Quebec</state>
        <zip>J2G 8Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Med Concorde</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7G 2E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultra-Med Inc.</name>
      <address>
        <city>Point Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique d'Urologie du Saguenay</name>
      <address>
        <city>Saguenay</city>
        <state>Quebec</state>
        <zip>G7H 4A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Récherche en Urologie de Lanaudiére</name>
      <address>
        <city>St. Charles-Baromee</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmount Med Bldg</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <zip>H4A 1S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Arts Bldg</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2008</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Prostatic adenoma</keyword>
  <keyword>Prostatic neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

